chico's fas stands for folk art specialties.
chico's fas stands for folk art specialties.
chico's fas what does fas stand for?
folk art specialties
the first franchise store opened in edina, minnesota in 1987. in 1989, the company shortened its name to chico's fas (an abbreviation for folk art specialties) and launched the passport loyalty rewards program.









































section::::history.:1991–2000.









































in 1991, chico's fas expanded into cities ranging from santa fe, new mexico to newport, rhode island. by 1992, the company operated 60 boutiques and began designing its own prints and patterns.
chico's (clothing retailer)
in molecular biology, fas antisense rna (non-protein coding), also known as fas-as1 or saf, is a long non-coding rna. in humans it is located on chromosome 10. in humans it is transcribed from the opposite strand of intron 1 of the fas gene. it may regulate the expression of some isoforms of fas. it may also play a role in the regulation of fas-mediated apoptosis. recently it has been shown be sehgal et al. that the alternative splicing of fas in lymphomas is tightly regulated by a long-noncoding rna corresponding to an antisense transcript of fas (fas-as1). levels of fas-as1 correlate inversely with production of sfas, and fas-as1 binding to the rbm5 inhibits rbm5-mediated exon 6 skipping. ezh2, often mutated or overexpressed in lymphomas, hyper-methylates the fas-as1 promoter and represses the fas-as1 expression. ezh2-mediated repression of fas-as1 promoter can be released by dznep (3-deazaneplanocin a) or overcome by ectopic expression of fas-as1, both of which increase levels of fas-as1 and correspondingly decrease expression of sfas. treatment with bruton’s tyrosine kinase inhibitor or ezh2 knockdown decreases the levels of ezh2, rbm5 and sfas, thereby enhancing fas-mediated apoptosis. this is the first report showing functional regulation of fas repression by its antisense rna. our results reveal new therapeutic targets in lymphomas and provide a rationale for the use of ezh2 inhibitors or ibrutinib in combination with chemotherapeutic agents that recruit fas for effective cell killing.
fas-as1